MyMD Pharmaceuticals, Inc. MYMD
Day range unavailable
52-week range unavailable
- Market cap
- 4.31M
- Shares out
- 2.37M
- Beta
- 2.69
- Earnings date
- May 15, 2024
6M -3.28 (-64.31%)
Key statistics
- Enterprise value
- 3.36M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -4.93M
- Total cash
- 1.74M
- Total debt
- 35.98K
- Return on equity
- -101.35%
- Short % of float
- 14.70%
- 50-day average
- 1.92
- 200-day average
- 4.23
Next earnings
May 15, 2024
Expected May 15, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 31, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 10, 2022 | Sep 1, 2022 | 0.00 | — | — | — |
About MyMD Pharmaceuticals, Inc.
MyMD Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- mymd.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on MYMD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHAPMAN CHRISTOPHER C JR | President | Stock Award(Grant) | Apr 15, 2021 | 96,475 |
| GORMALLY JOHN J | Chief Executive Officer | Stock Award(Grant) | Oct 16, 2017 | 180,000 |
| HUDSON BAY CAPITAL MANAGEMENT, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 27, 2020 | 0 |
| HUDSON BAY CAPITAL MANAGEMENT. L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 27, 2020 | 0 |
| RIVARD PAUL | Officer | Purchase | Aug 23, 2023 | 400,000 |
| SCHREIBER CHRISTOPHER C | Director | Conversion of Exercise of derivative security | Apr 15, 2021 | 88,238 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 3.25% | 1,458,295 | 2.19M | Jun 29, 2023 |
| Mirae Asset Global Investments Co., Ltd. | 2.63% | 1,183,616 | 1.78M | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.63% | 282,250 | 423.38K | Jun 29, 2023 |
| Blackrock Inc. | 0.47% | 210,965 | 316.45K | Jun 29, 2023 |
| Praetorian Wealth Management, Inc. | 0.45% | 200,000 | 118.40K | Sep 29, 2023 |
| Wells Fargo & Company | 0.36% | 163,244 | 244.87K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.20% | 986,327 | 1.48M | Jun 29, 2023 |
| Global X Fds-The Global X Cannabis ETF | 2.08% | 934,512 | 553.23K | Sep 29, 2023 |
| Vanguard Extended Market Index Fund | 0.91% | 410,666 | 616.00K | Jun 29, 2023 |
| Cambria ETF Tr-Cambria Cannabis ETF | 0.38% | 171,570 | 101.57K | Sep 29, 2023 |
| Fidelity Extended Market Index Fund | 0.34% | 151,441 | 263.51K | May 30, 2023 |
| iShares Micro Cap ETF | 0.19% | 86,322 | 82.14K | Aug 30, 2023 |